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Abstract
Background: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal-dominant inherited disorder that is
classically characterized by the presence of neoplastic lesions of the parathyroid glands, the anterior pituitary gland,
and the pancreas. However, MEN1 with concomitant pheochromocytoma is extremely rare.
Case report: We report a case of MEN1 concomitant with pheochromocytoma. A 44-year-old Japanese man, who
had undergone total parathyroidectomy due to primary hyperparathyroidism at the age of 18, was referred to our
hospital with a complaint of a large abdominal tumor. He was diagnosed as having a giant insulinoma (maximum
diameter 18 cm) in the pancreatic tail, five other non-functional neuroendocrine tumors in the pancreatic body and
tail, multiple liver metastases of pancreatic neuroendocrine tumors, a pituitary prolactinoma, non-functional adrenal
cortical adenomas, a pheochromocytoma in addition to a subcutaneous neurofibroma, and a cutaneous fibroma.
The genetic screening revealed a deletion mutation at codons 83–84 in exon 2 of the MEN1 gene. He underwent
distal pancreatectomy, splenectomy, cholecystectomy, right adrenalectomy, abdominal subcutaneous tumor
excision, and cutaneous tumor biopsy for the purpose of tumor volume reduction. Extended right posterior
segmentectomy with partial hepatectomy of S2, S3, and S8 was performed to resect residual tumors 9 months after
the initial surgery. Although a newly formed liver metastasis was found 19 months after the hepatectomy, he is still
alive 4 years and 4 months after the initial surgery.
Conclusions: We reported an extremely rare case of giant insulinoma and simultaneous occurrence of
pheochromocytoma and adrenal cortical adenoma in the ipsilateral adrenal gland in a patient clinically and
genetically diagnosed as having MEN1.
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Background
Multiple endocrine neoplasia type 1 (MEN1) is an
autosomal-dominant inherited disorder that is classically
characterized by the presence of neoplastic lesions of the
parathyroid glands, the anterior pituitary gland, and the
pancreas [1–4]. Furthermore, multiple benign and malig-
nant tumors occur in regions such as the adrenal cortex,
the thymus, the bronchi, and the skin. The MEN1 gene
was identified in 1997 and is located on chromosome
11q13 encoding a 610-amino acid protein, MENIN [2].
Insulinoma, one of the pancreatic neuroendocrine tu-
mors (NETs) of MEN1, causes obvious symptoms even
small in size due to hypoglycemia and is usually found
small (less than 2.0 cm) at diagnosis [5]. An incidence of
adrenal involvement in patients with MEN1 is about
20 % [4], most of which lesions are derived from the ad-
renal cortex [4].
* Correspondence: r-okada@fmu.ac.jp
1Department of Organ Regulatory Surgery, Fukushima Medical University,
Fukushima, Japan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Okada et al. Surgical Case Reports  (2016) 2:84 
DOI 10.1186/s40792-016-0214-x
We report herein a case of MEN1 with a giant insuli-
noma of the pancreatic tail, non-functional adrenal cor-
tical adenomas, and an ipsilateral pheochromocytoma.
Case presentation
A 44-year-old Japanese man was referred to our hospital
complaining of a large tumor that had been accidentally
pointed out in a medical examination as being an esopha-
geal submucosal tumor. Relevant family history brought to
light that his father had been diagnosed as having MEN1.
Our patient had undergone total parathyroidectomy and
autologous transplantation for primary hyperparathyroid-
ism at the age of 18. His height and weight were 187 cm
and 120 kg, respectively, with a body mass index of 34 kg/
m2 on admission. He also complained of sleep apnea and
bilateral nipple discharge. He was not aware of the
hypoglycemic symptoms before the admission, but he fre-
quently encountered the symptoms under nutritional man-
agement after the admission. Laboratory data of blood
chemistry were normal as well as the tumor markers, such
as carcinoembryonic antigen and carbohydrate antigen 19-
9, whereas neuron specific γ-enolase was high (19.1 ng/ml).
Hormonal examinations revealed a hypoglycemia, a hyper-
insulinemia (fasting serum glucose, insulin levels, and
hemoglobin A1c, 76 mg/dl, 134.5 μU/ml, and 4.5 %,
respectively), a hyperprolactinemia (serum prolactin level
871.2 ng/ml), and elevated urinary catecholamines. On an
enhanced thin-slice abdominal computed tomography
(CT), a large tumor was detected in the pancreatic tail,
showing heterogeneous enhancement with partial calcifica-
tion and cystic components. Its maximum diameter was
about 18 cm (Fig.1a, b). Other than a pancreatic tail tumor,
six enhanced liver tumors, a right adrenal tumor (3.9 cm in
diameter), and a left adrenal tumor (2.6 cm in diameter)
were found (Fig. 1c, d). The right adrenal tumor was het-
erogeneously enhanced. An endoscopic ultrasonography
(EUS) revealed four tumors in the body and tail of the pan-
creas, except for the giant tumor, and abundant blood flow
in all these tumors. Immunohistochemical examinations of
a EUS-guided fine-needle aspiration biopsy showed that
the giant pancreatic tumor and liver tumors were positive
for chromogranin A, synaptophysin, and CD56; thus, the
tumors were diagnosed as being a pancreatic neuroendo-
crine tumor (NET) and its liver metastases. They were
NET G1 as the labeling index of Ki67 was 1.8 %. A calcium
gluconate injection into the distal splenic artery during a
selective intra-arterial calcium injection test resulted in a
marked increase in serum insulin and C-peptide. Both 123I-
metaiodobenzylguanidine scintigraphy and 131I-adosterol
scintigraphy showed high radioactivity in the right adrenal
Fig. 1 a, b Computed tomographic image of the abdomen, demonstrating a large was heterogeneously enhanced insulinoma arising from the
tail of the pancreas. c Computed tomographic image of the abdomen, demonstrating a ring-enhanced tumor of the right adrenal gland (arrow).
d Computed tomographic image of the abdomen, demonstrating a poor-enhanced tumor of the left adrenal gland (arrow)
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tumor and no radioactivity in the left one. The left adrenal
tumor was therefore diagnosed as having a non-functional
adenoma. A magnetic resonance imaging (MRI) identified
a heterogeneous pituitary adenoma, 3.1 cm in diameter.
His pedigree diagram is shown in Fig. 2. Five patients
with MEN1, including our patient who has anMEN1 gene
mutation, were identified within his family. Furthermore,
the genetic examination revealed a deletion mutation
(g.249_252delGTCT) at codons 83–84 in exon 2. He
underwent distal pancreatectomy, splenectomy, cholecyst-
ectomy, right adrenalectomy, abdominal subcutaneous
tumor excision, and cutaneous tumor biopsy for the pur-
pose of tumor volume reduction. Six tumors in the resected
pancreas were diagnosed as being pancreatic NETs. The
giant tumor in the pancreatic tail was insulinoma, and NET
G2 as the Ki67 labeling index was 4.2 % (Fig. 3). Of the
other five lesions, two tumors consisted of the insulin-
positive tumor cells with less than 0.1 % of the Ki67 index,
and three tumors consisted of the glucagon-positive tumor
cells with less than 0.1 % of the Ki67 index. These tumors
were diagnosed as being non-functional NET G1 because
no symptom due to a glucagon excess was encountered.
A non-functional adrenal cortical adenoma, measuring
1.3 cm in maximum diameter, and a pheochromocytoma,
measuring 4.7 cm in maximum diameter, coexisted in the
right adrenal gland (Fig. 4). The abdominal subcutaneous
tumor was found to be a neurofibroma, and the cutaneous
tumor was a fibroma.
During the postoperative outpatient follow-up, he de-
veloped diabetes mellitus and required treatment with
an oral antidiabetic drug. For the treatment of his pituitary
prolactinoma, cabergoline was administered. Octreotide
therapy for the multiple liver metastases of the NETs began
2 months after the operation. After the ninth administra-
tion of the octreotide, three new lesions were detected in
the liver on a CT scan. His general condition was judged
to be tolerable to undergo liver resection, and the radio-
logical examinations showed that there was no recurrence
except the liver. Complete surgical resection of liver metas-
tases was therefore achieved by an extended right posterior
segmentectomy with partial hepatectomy of S2, S3, and S8.
Immunohistochemical examination revealed that liver me-
tastases were derived from a glucagon-positive tumor of
the pancreatic NET. The Ki67 labeling index of these le-
sions ranged from 1.5 to 5.4 %.
Nineteen months after the hepatectomy, a CT scan re-
vealed a small nodule in the S4 of the liver. Twenty-
three months after the hepatectomy, gadoxetic acid- or
gadolinium ethoxybenzyl diethylenetriamine pentaacetic
acid-enhanced MRI demonstrated multiple liver tumors.
Fig. 2 Family pedigree. This family pedigree was made according the standardized human pedigree nomenclature of the National Society of
Genetic Counselors. III-1 shows our patient. I-2, II-1, II-2, II-3, II-5, II-6, III-1, and III-2 received the genetic examination. NET neuroendocrine tumor
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We started everolimus therapy following a diagnosis of
unresectable pancreatic NET recurrence. He is still alive
after 4 years and 4 months after the initial surgery, al-
though he is suffering from worsened diabetes mellitus,
a pituitary prolactinoma that led to a hemorrhage into
the pituitary tumor, and an increasing size of the left
nonfunctional adrenal tumor.
Discussion
MEN1 is an autosomal-dominant hereditary syndrome
caused by germline mutations of the MENIN gene that
predisposes the development of endocrine and non-
endocrine tumors with variable penetrance [1–4, 6]. The
most frequent tumors in MEN1 patients arise in the
parathyroid glands, the pancreas, and the pituitary gland
[4, 6, 7]. The incidence of pancreatic NETs is reported to
be from 50 to 70 %. Insulinoma is one of the pancreatic
NETs arising in the setting of MEN1. In Japan, the mean
tumor size of pancreatic NETs was reported to be
3.03 cm at the time of diagnosis [5], whereas that of
insulinoma was smaller than 2 cm in approximately 70 %
of insulinoma patients, probably because insulinoma is a
symptomatic disorder [5]. There are some previous re-
ports on a giant insulinoma [8–12], and the insulinoma
with a diameter of 18 cm in the present case is the second
largest by referring to the previous reports. Moreover, only
the present case did not complain of hypoglycemic symp-
toms, whereas all other patients with giant insulinoma
presented such symptoms. The reasons why the present
case showed no hypoglycemic symptoms were unclear;
however, we can propose some hypotheses for this: pheo-
chromocytoma might reduce hypoglycemia due to insuli-
noma; at the time of hypoglycemia, our patient overate
unconsciously; and glucagon secreted from glucagon-
positive tumor cells compensates hypoglycemia.
More than a half of the patients with a giant insulinoma
reportedly had a liver metastasis at the time of diagnosis.
Liver metastases of the present case were estimated to be
derived from the glucagon-positive cells of the pancreatic
NET. This was consistent with the consensus that non-
Fig. 3 a Excised insulinoma, measuring 18.0 × 13.0 × 12.0 cm. b Hematoxylin-eosin staining of the insulinoma (×400). c Tumor cells are positive in
the immunohistochemical staining for chromograin A (×400). d Ki67 is 4.3 % (×400). e Tumor cells are focally positive for insulin (×400)
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functional tumor have a higher incidence of liver metasta-
ses than insulinoma [5]. On the other hand, the fact that
the Ki67 labeling index of metastatic tumors was higher
than that of the primary tumors suggested that highly pro-
liferative components had more potential to form meta-
static lesions.
An incidence of adrenal involvement in patients with
MEN1 is about 20 % [4], most of which lesions are derived
from the adrenal cortex. Concomitant pheochromocytoma
is rare [6, 13]. Corticomedullary mixed tumor is a single
adrenal tumor mass composed of an intimately admixed
population of both adrenal cortical cells and pheochromo-
cytes [14]. However, in our case, adrenal cortical adenoma
and pheochromocytoma separately coexisted in the same
adrenal gland, which is extremely rare [15–19], and even
more so in the setting of the MEN1.
Conclusions
In conclusion, we reported an extremely rare case of a
giant insulinoma and simultaneous occurrence of pheo-
chromocytoma and adrenal cortical adenoma in the ipsi-
lateral adrenal gland in a patient clinically and genetically
diagnosed as having MEN1.
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